Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma-a review

Tumour Biol. 2016 Nov;37(11):14443-14450. doi: 10.1007/s13277-016-5373-7. Epub 2016 Sep 18.

Abstract

Esophageal cancer is one of the most malignant gastrointestinal cancers worldwide. Despite advances in surgical technique, 5-year survival in pathologic stage T2-3N0M0 esophageal squamous cell carcinoma patients who are treated with surgery alone is still poor. The addition of adjuvant radiotherapy may confer a benefit for these patients. However, not all patients could get a benefit from radiotherapy and patients with esophageal squamous cell carcinoma receiving radiotherapy seem to have a disparity in treatment response. Thus, identifying effective prognostic indicator to complement current clinical staging approaches is extremely important. Those prognostic factors could give rise to a novel prognostic stratification system, which serve as criteria for selecting patients for adjuvant therapy. Consequently, it may help to define the subgroups who are more likely to benefit from postoperative radiation therapy.

Keywords: Esophageal squamous cell carcinoma; Postoperative; Prognosis factors; Prognostic assessment; Radiation therapy; Therapeutic evaluation.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / surgery*
  • Combined Modality Therapy / methods
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / radiotherapy*
  • Esophageal Neoplasms / surgery*
  • Esophageal Squamous Cell Carcinoma
  • Humans
  • Neoplasm Staging
  • Postoperative Period
  • Prognosis
  • Radiotherapy, Adjuvant / methods*
  • Survival Rate